Conference Coverage

Ibrutinib tops chlorambucil against CLL

AMSTERDAM – The Bruton’s tyrosine kinase inhibitor was associated with a halving of risk for death, compared with chlorambucil.

Conference Coverage

R2-CHOP doesn’t improve survival in DLBCL

LUGANO, SWITZERLAND – The ROBUST trial is the latest in a long line of studies that failed to show improvement in outcomes with the addition of a...